{"protocolSection": {"identificationModule": {"nctId": "NCT01368536", "orgStudyIdInfo": {"id": "CSPV100AUS05"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes", "officialTitle": "A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes", "acronym": "VALENCIA"}, "statusModule": {"statusVerifiedDate": "2013-03", "overallStatus": "TERMINATED", "whyStopped": "Based on results from an ALTITUDE study interim analysis, testing aliskiren concomitantly with an ACE inhibitor or ARB, in diabetics with renal impairment", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-05"}, "primaryCompletionDateStruct": {"date": "2012-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-06-06", "studyFirstSubmitQcDate": "2011-06-07", "studyFirstPostDateStruct": {"date": "2011-06-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-02-14", "resultsFirstSubmitQcDate": "2013-02-14", "resultsFirstPostDateStruct": {"date": "2013-03-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-03-18", "lastUpdatePostDateStruct": {"date": "2013-03-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This was a study to assess the safety and efficacy of Valturna and amlodipine or Valturna and chlorthalidone when compared to Valturna alone in patients with stage 2 hypertension and diabetes mellitus 2."}, "conditionsModule": {"conditions": ["Hypertension", "Stage 2 Hypertension", "Diabetes"], "keywords": ["High blood pressure", "diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 975, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Valturna", "type": "EXPERIMENTAL", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks.", "interventionNames": ["Drug: Valturna", "Drug: Placebo of Valturna Tablet", "Drug: Placebo Capsule"]}, {"label": "Valturna + Amlodipine", "type": "ACTIVE_COMPARATOR", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks.", "interventionNames": ["Drug: Valturna", "Drug: Amlodipine", "Drug: Placebo of Valturna Tablet", "Drug: Placebo Capsule"]}, {"label": "Valturna + chlorthalidone", "type": "ACTIVE_COMPARATOR", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks.", "interventionNames": ["Drug: Valturna", "Drug: Chlorthalidone", "Drug: Placebo of Valturna Tablet", "Drug: Placebo Capsule"]}], "interventions": [{"type": "DRUG", "name": "Valturna", "description": "Valturna (aliskiren 150 mg/valsartan 160 mg) tablet", "armGroupLabels": ["Valturna", "Valturna + Amlodipine", "Valturna + chlorthalidone"]}, {"type": "DRUG", "name": "Amlodipine", "description": "Amlodipine 5 mg and 10 mg capsule", "armGroupLabels": ["Valturna + Amlodipine"]}, {"type": "DRUG", "name": "Chlorthalidone", "description": "Chlorthalidone 15 mg and 25 mg capsule", "armGroupLabels": ["Valturna + chlorthalidone"]}, {"type": "DRUG", "name": "Placebo of Valturna Tablet", "description": "Matching placebo of valturna tablet", "armGroupLabels": ["Valturna", "Valturna + Amlodipine", "Valturna + chlorthalidone"]}, {"type": "DRUG", "name": "Placebo Capsule", "description": "Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule", "armGroupLabels": ["Valturna", "Valturna + Amlodipine", "Valturna + chlorthalidone"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) After 12 Weeks of Treatment Ending With the Combination of Valturna and Amlodipine Versus Valturna Alone", "description": "Sitting BP was measured at trough (24 hours \u00b1 3 hours postdose) and recorded at all study visits. At the first study visit, the patient had his/her BP measured in both arms; the arm in which the highest sitting DBP was found was used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for 5 minutes, SBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit.", "timeFrame": "Baseline, 12 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in MSSBP After 12 Weeks of Treatment Ending With Between the Valturna + Chlorthalidone Combination and Valturna Alone", "description": "Sitting BP was measured at trough (24 hours \u00b1 3 hours postdose) and recorded at all study visits. At the first study visit, the patient had his/her BP measured in both arms; the arm in which the highest sitting DBP was found was used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for 5 minutes, SBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit.", "timeFrame": "Baseline, 12 weeks"}, {"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) After 12 Weeks of Treatment", "description": "Sitting blood pressure (BP) was measured at trough (24 hours \u00b1 3 hours postdose) and recorded at all study visits. At the first study visit, the patient had his/her BP measured in both arms; the arm in which the highest sitting DBP was found was used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for 5 minutes, DBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit.", "timeFrame": "Baseline, 12 weeks"}, {"measure": "Percentage of Responders After Treatment", "description": "Responders are defined as patients with MSSBP \\<130 mmHg or a decrease from baseline in MSSBP of \u226520 mmHg", "timeFrame": "Baseline, 12 weeks"}, {"measure": "Percentage of Patients Achieving Blood Pressure Control After Treatment", "description": "Patient with blood pressure control is defined as patients achieving MSSBP \\<130 mmHg and MSDBP \\<80 mmHg.", "timeFrame": "12 weeks"}, {"measure": "Number of Patients With Adverse Events, Serious Adverse Events and Death to Assess Safety and Tolerability of Treatment With Valturna and Chlorthalidone or Valturna and Amlodipine Versus Valturna Alone", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with stage 2 hypertension within protocol limits at randomization\n* Patients with type 2 diabetes mellitus with HgA1c less than or equal to 9%\n* Patients with newly diagnosed hypertension or patients who have not received antihypertensive therapy for at least 4 weeks prior to screening\n\nExclusion Criteria:\n\n* Patients taking 4 or more antihypertensive medications at screening visit\n* Patients with uncontrolled BP (\\> 140/90 mmHg) while taking 3 or more antihypertensives at their maximum approved doses\n* Type 2 diabetes mellitus requiring insulin treatment\n* Patients with HgA1c \\> 9%\n* Patients with known gout\n* Known history of cancer within the past 5 years\n* Patients who are pregnant or nursing mothers\n* Patients who have participated in an investigational clinical trial within the 30 days prior to screening.\n* Other protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Athens", "state": "Alabama", "zip": "35611", "country": "United States", "geoPoint": {"lat": 34.80243, "lon": -86.97219}}, {"facility": "Novartis Investigative Site", "city": "Florence", "state": "Alabama", "zip": "35630", "country": "United States", "geoPoint": {"lat": 34.79981, "lon": -87.67725}}, {"facility": "Novartis Investigative Site", "city": "Huntsville", "state": "Alabama", "zip": "35801", "country": "United States", "geoPoint": {"lat": 34.7304, "lon": -86.58594}}, {"facility": "Novartis Investigative Site", "city": "Montgomery", "state": "Alabama", "zip": "36106", "country": "United States", "geoPoint": {"lat": 32.36681, "lon": -86.29997}}, {"facility": "Novartis Investigative Site", "city": "Muscle Shoals", "state": "Alabama", "zip": "35662", "country": "United States", "geoPoint": {"lat": 34.74481, "lon": -87.66753}}, {"facility": "Novartis Investigative Site", "city": "Chandler", "state": "Arizona", "zip": "85224", "country": "United States", "geoPoint": {"lat": 33.30616, "lon": -111.84125}}, {"facility": "Novartis Investigative Site", "city": "Little Rock", "state": "Arkansas", "zip": "72204", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Novartis Investigative Site", "city": "Buena Park", "state": "California", "zip": "90620", "country": "United States", "geoPoint": {"lat": 33.86751, "lon": -117.99812}}, {"facility": "Novartis Investigative Site", "city": "Fair Oaks", "state": "California", "zip": "95628", "country": "United States", "geoPoint": {"lat": 38.64463, "lon": -121.27217}}, {"facility": "Novartis Investigative Site", "city": "Fresno", "state": "California", "zip": "93726", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Novartis Investigative Site", "city": "Healdsburg", "state": "California", "zip": "95448", "country": "United States", "geoPoint": {"lat": 38.61047, "lon": -122.86916}}, {"facility": "Novartis Investigative Site", "city": "Los Angeles", "state": "California", "zip": "90057", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Novartis Investigative Site", "city": "Orangevale", "state": "California", "zip": "95662", "country": "United States", "geoPoint": {"lat": 38.67851, "lon": -121.22578}}, {"facility": "Novartis Investigative Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Novartis Investigative Site", "city": "Roseville", "state": "California", "zip": "95661", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"facility": "Novartis Investigative Site", "city": "Sacramento", "state": "California", "zip": "95816", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Novartis Investigative Site", "city": "Santa Ana", "state": "California", "zip": "92701", "country": "United States", "geoPoint": {"lat": 33.74557, "lon": -117.86783}}, {"facility": "Novartis Investigative Site", "city": "West Covina", "state": "California", "zip": "91790", "country": "United States", "geoPoint": {"lat": 34.06862, "lon": -117.93895}}, {"facility": "Novartis Investigative Site", "city": "Shelton", "state": "Connecticut", "zip": "06484", "country": "United States", "geoPoint": {"lat": 41.31649, "lon": -73.09316}}, {"facility": "Novartis Investigative Site", "city": "Fort Lauderdale", "state": "Florida", "zip": "33306", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"facility": "Novartis Investigative Site", "city": "Ft. Lauderdale", "state": "Florida", "zip": "33308", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"facility": "Novartis Investigative Site", "city": "Jupiter", "state": "Florida", "zip": "33458", "country": "United States", "geoPoint": {"lat": 26.93422, "lon": -80.09421}}, {"facility": "Novartis Investigative Site", "city": "Lauderdale Lakes", "state": "Florida", "zip": "33319", "country": "United States", "geoPoint": {"lat": 26.16647, "lon": -80.20838}}, {"facility": "Novartis Investigative Site", "city": "North Miami Beach", "state": "Florida", "zip": "33169", "country": "United States", "geoPoint": {"lat": 25.93315, "lon": -80.16255}}, {"facility": "Novartis Investigative Site", "city": "St. Petersburg", "state": "Florida", "zip": "33701", "country": "United States", "geoPoint": {"lat": 27.77086, "lon": -82.67927}}, {"facility": "Novartis Investigative Site", "city": "Tampa", "state": "Florida", "zip": "33603", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Novartis Investigative Site", "city": "West Palm Beach", "state": "Florida", "zip": "33409", "country": "United States", "geoPoint": {"lat": 26.71534, "lon": -80.05337}}, {"facility": "Novartis Investigative Site", "city": "Augusta", "state": "Georgia", "zip": "30904", "country": "United States", "geoPoint": {"lat": 33.47097, "lon": -81.97484}}, {"facility": "Novartis Investigative Site", "city": "Honolulu", "state": "Hawaii", "zip": "96813", "country": "United States", "geoPoint": {"lat": 21.30694, "lon": -157.85833}}, {"facility": "Novartis Investigative Site", "city": "Chicago", "state": "Illinois", "zip": "60607", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Novartis Investigative Site", "city": "Chicago", "state": "Illinois", "zip": "60610", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Novartis Investigative Site", "city": "Chicago", "state": "Illinois", "zip": "60617", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Novartis Investigative Site", "city": "Gurnee", "state": "Illinois", "zip": "60031", "country": "United States", "geoPoint": {"lat": 42.3703, "lon": -87.90202}}, {"facility": "Novartis Investigative Site", "city": "Lansing", "state": "Kansas", "zip": "66043", "country": "United States", "geoPoint": {"lat": 39.24861, "lon": -94.90024}}, {"facility": "Novartis Investigative Site", "city": "Topeka", "state": "Kansas", "zip": "66606", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"facility": "Novartis Investigative Site", "city": "Beltsville", "state": "Maine", "zip": "20705", "country": "United States"}, {"facility": "Novartis Investigative Site", "city": "Waltham", "state": "Massachusetts", "zip": "02453", "country": "United States", "geoPoint": {"lat": 42.37649, "lon": -71.23561}}, {"facility": "Novartis Investigative Site", "city": "Wellesley Hills", "state": "Massachusetts", "zip": "02481-2106", "country": "United States", "geoPoint": {"lat": 42.30843, "lon": -71.27867}}, {"facility": "Novartis Investigative Site", "city": "Brooklyn Center", "state": "Minnesota", "zip": "55430-2168", "country": "United States", "geoPoint": {"lat": 45.07608, "lon": -93.33273}}, {"facility": "Novartis Investigative Site", "city": "Belzoni", "state": "Mississippi", "zip": "39038", "country": "United States", "geoPoint": {"lat": 33.18429, "lon": -90.48926}}, {"facility": "Novartis Investigative Site", "city": "Jackson", "state": "Mississippi", "zip": "39209", "country": "United States", "geoPoint": {"lat": 32.29876, "lon": -90.18481}}, {"facility": "Novartis Investigative Site", "city": "Picayune", "state": "Mississippi", "zip": "39466", "country": "United States", "geoPoint": {"lat": 30.52556, "lon": -89.67788}}, {"facility": "Novartis Investigative Site", "city": "Kansas City", "state": "Missouri", "zip": "64111", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Novartis Investigative Site", "city": "Ozark", "state": "Missouri", "zip": "65721", "country": "United States", "geoPoint": {"lat": 37.02089, "lon": -93.20602}}, {"facility": "Novartis Investigative Site", "city": "St. Louis", "state": "Missouri", "zip": "63110-1093", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigative Site", "city": "St. Louis", "state": "Missouri", "zip": "63128", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigative Site", "city": "St. Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigative Site", "city": "Omaha", "state": "Nebraska", "zip": "68134", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Novartis Investigative Site", "city": "Henderson", "state": "Nevada", "zip": "89014", "country": "United States", "geoPoint": {"lat": 36.0397, "lon": -114.98194}}, {"facility": "Novartis Investigative Site", "city": "Las Vegas", "state": "Nevada", "zip": "89119", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Novartis Investigative Site", "city": "Toms River", "state": "New Jersey", "zip": "08753", "country": "United States", "geoPoint": {"lat": 39.95373, "lon": -74.19792}}, {"facility": "Novartis Investigative Site", "city": "Toms River", "state": "New Jersey", "zip": "08755", "country": "United States", "geoPoint": {"lat": 39.95373, "lon": -74.19792}}, {"facility": "Novartis Investigative Site", "city": "Trenton", "state": "New Jersey", "zip": "08629", "country": "United States", "geoPoint": {"lat": 40.21705, "lon": -74.74294}}, {"facility": "Novartis Investigative Site", "city": "Buffalo", "state": "New York", "zip": "14209", "country": "United States", "geoPoint": {"lat": 42.88645, "lon": -78.87837}}, {"facility": "Novartis Investigative Site", "city": "Camillus", "state": "New York", "zip": "13031", "country": "United States", "geoPoint": {"lat": 43.03923, "lon": -76.3041}}, {"facility": "Novartis Investigative Site", "city": "Asheboro", "state": "North Carolina", "zip": "27204", "country": "United States", "geoPoint": {"lat": 35.70791, "lon": -79.81364}}, {"facility": "Novartis Investigative Site", "city": "Asheville", "state": "North Carolina", "zip": "28801", "country": "United States", "geoPoint": {"lat": 35.60095, "lon": -82.55402}}, {"facility": "Novartis Investigative Site", "city": "Greensboro", "state": "North Carolina", "zip": "27401", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"facility": "Novartis Investigative Site", "city": "Greensboro", "state": "North Carolina", "zip": "27408", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"facility": "Novartis Investigative Site", "city": "Shelby", "state": "North Carolina", "zip": "28150", "country": "United States", "geoPoint": {"lat": 35.29235, "lon": -81.53565}}, {"facility": "Novartis Investigative Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Novartis Investigative Site", "city": "Fargo", "state": "North Dakota", "zip": "58103", "country": "United States", "geoPoint": {"lat": 46.87719, "lon": -96.7898}}, {"facility": "Novartis Investigative Site", "city": "Cincinnati", "state": "Ohio", "zip": "45219", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Novartis Investigative Site", "city": "Cincinnati", "state": "Ohio", "zip": "45224", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Novartis Investigative Site", "city": "Columbus", "state": "Ohio", "zip": "43201", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Novartis Investigative Site", "city": "Lyndhurst", "state": "Ohio", "zip": "44124", "country": "United States", "geoPoint": {"lat": 41.52005, "lon": -81.48873}}, {"facility": "Novartis Investigative Site", "city": "Zanesville", "state": "Ohio", "zip": "43701", "country": "United States", "geoPoint": {"lat": 39.94035, "lon": -82.01319}}, {"facility": "Novartis Investigative Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73132-4904", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novartis Investigative Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73134", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novartis Investigative Site", "city": "Portland", "state": "Oregon", "zip": "97232", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Novartis Investigative Site", "city": "Reading", "state": "Pennsylvania", "zip": "19609", "country": "United States", "geoPoint": {"lat": 40.33565, "lon": -75.92687}}, {"facility": "Novartis Investigative Site", "city": "Uniontown", "state": "Pennsylvania", "zip": "15401", "country": "United States", "geoPoint": {"lat": 39.90008, "lon": -79.71643}}, {"facility": "Novartis Investigative Site", "city": "Wallingford", "state": "Pennsylvania", "zip": "19086", "country": "United States", "geoPoint": {"lat": 39.89095, "lon": -75.36297}}, {"facility": "Novartis Investigative Site", "city": "Charleston", "state": "South Carolina", "zip": "29407", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Novartis Investigative Site", "city": "Charleston", "state": "South Carolina", "zip": "29412", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Novartis Investigative Site", "city": "Easley", "state": "South Carolina", "zip": "29640", "country": "United States", "geoPoint": {"lat": 34.82984, "lon": -82.60152}}, {"facility": "Novartis Investigative Site", "city": "Greenville", "state": "South Carolina", "zip": "29615", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Novartis Investigative Site", "city": "Mt. Pleasant", "state": "South Carolina", "zip": "29464", "country": "United States", "geoPoint": {"lat": 32.79407, "lon": -79.86259}}, {"facility": "Novartis Investigative Site", "city": "Summerville", "state": "South Carolina", "zip": "29485", "country": "United States", "geoPoint": {"lat": 33.0185, "lon": -80.17565}}, {"facility": "Novartis Investigative Site", "city": "Varnville", "state": "South Carolina", "zip": "29944", "country": "United States", "geoPoint": {"lat": 32.85044, "lon": -81.07927}}, {"facility": "Novartis Investigative Site", "city": "Fayetteville", "state": "Tennessee", "zip": "33734", "country": "United States", "geoPoint": {"lat": 35.15203, "lon": -86.57055}}, {"facility": "Novartis Investigative Site", "city": "Arlington", "state": "Texas", "zip": "76012", "country": "United States", "geoPoint": {"lat": 32.73569, "lon": -97.10807}}, {"facility": "Novartis Investigative Site", "city": "Austin", "state": "Texas", "zip": "78728-6904", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Novartis Investigative Site", "city": "Austin", "state": "Texas", "zip": "78735", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Novartis Investigative Site", "city": "Dallas", "state": "Texas", "zip": "75235", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novartis Investigative Site", "city": "Houston", "state": "Texas", "zip": "77025", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigative Site", "city": "Houston", "state": "Texas", "zip": "77074", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigative Site", "city": "Houston", "state": "Texas", "zip": "77081", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigative Site", "city": "Houston", "state": "Texas", "zip": "77083", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigative Site", "city": "Lake Jackson", "state": "Texas", "zip": "77566", "country": "United States", "geoPoint": {"lat": 29.03386, "lon": -95.43439}}, {"facility": "Novartis Investigative Site", "city": "Pasadena", "state": "Texas", "zip": "77504", "country": "United States", "geoPoint": {"lat": 29.69106, "lon": -95.2091}}, {"facility": "Novartis Investigative Site", "city": "Plano", "state": "Texas", "zip": "75093", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Novartis Investigative Site", "city": "Richardson", "state": "Texas", "zip": "75080", "country": "United States", "geoPoint": {"lat": 32.94818, "lon": -96.72972}}, {"facility": "Novartis Investigative Site", "city": "St. George", "state": "Utah", "zip": "84790", "country": "United States", "geoPoint": {"lat": 37.10415, "lon": -113.58412}}, {"facility": "Novartis Investigative Site", "city": "Arlington", "state": "Virginia", "zip": "22203", "country": "United States", "geoPoint": {"lat": 38.88101, "lon": -77.10428}}, {"facility": "Novartis Investigative Site", "city": "Carolina", "zip": "00983", "country": "Puerto Rico", "geoPoint": {"lat": 18.38078, "lon": -65.95739}}, {"facility": "Novartis Investigative Site", "city": "San Juan", "zip": "00926", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of the 975 patients screened, 417 were randomized.", "groups": [{"id": "FG000", "title": "Valturna", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks."}, {"id": "FG001", "title": "Valturna + Amlodipine", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks."}, {"id": "FG002", "title": "Valturna + Chlorthalidone", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "138"}, {"groupId": "FG001", "numSubjects": "137"}, {"groupId": "FG002", "numSubjects": "142"}]}, {"type": "Full Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "138"}, {"groupId": "FG001", "numSubjects": "137"}, {"groupId": "FG002", "comment": "One patient was excluded from efficacy analysis as there was no post baseline data", "numSubjects": "141"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "87"}, {"groupId": "FG001", "numSubjects": "78"}, {"groupId": "FG002", "numSubjects": "83"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "51"}, {"groupId": "FG001", "numSubjects": "59"}, {"groupId": "FG002", "numSubjects": "59"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "Abnormal laboratory value(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Abnormal test procedure result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "No longer required study medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "39"}, {"groupId": "FG002", "numSubjects": "35"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Valturna", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks."}, {"id": "BG001", "title": "Valturna + Amlodipine", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks."}, {"id": "BG002", "title": "Valturna + Chlorthalidone", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "138"}, {"groupId": "BG001", "value": "137"}, {"groupId": "BG002", "value": "141"}, {"groupId": "BG003", "value": "416"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.7", "spread": "8.65"}, {"groupId": "BG001", "value": "56.0", "spread": "9.56"}, {"groupId": "BG002", "value": "54.6", "spread": "9.35"}, {"groupId": "BG003", "value": "55.1", "spread": "9.20"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "73"}, {"groupId": "BG002", "value": "70"}, {"groupId": "BG003", "value": "216"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "65"}, {"groupId": "BG001", "value": "64"}, {"groupId": "BG002", "value": "71"}, {"groupId": "BG003", "value": "200"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) After 12 Weeks of Treatment Ending With the Combination of Valturna and Amlodipine Versus Valturna Alone", "description": "Sitting BP was measured at trough (24 hours \u00b1 3 hours postdose) and recorded at all study visits. At the first study visit, the patient had his/her BP measured in both arms; the arm in which the highest sitting DBP was found was used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for 5 minutes, SBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit.", "populationDescription": "The study was terminated and consequentially was underpowered for adequate statistical analysis", "reportingStatus": "POSTED", "timeFrame": "Baseline, 12 weeks", "groups": [{"id": "OG000", "title": "Valturna", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks."}, {"id": "OG001", "title": "Valturna + Amlodipine", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in MSSBP After 12 Weeks of Treatment Ending With Between the Valturna + Chlorthalidone Combination and Valturna Alone", "description": "Sitting BP was measured at trough (24 hours \u00b1 3 hours postdose) and recorded at all study visits. At the first study visit, the patient had his/her BP measured in both arms; the arm in which the highest sitting DBP was found was used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for 5 minutes, SBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit.", "populationDescription": "The study was terminated and consequentially was underpowered for adequate statistical analysis", "reportingStatus": "POSTED", "timeFrame": "Baseline, 12 weeks", "groups": [{"id": "OG000", "title": "Valturna", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks."}, {"id": "OG001", "title": "Valturna + Chlorthalidone", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) After 12 Weeks of Treatment", "description": "Sitting blood pressure (BP) was measured at trough (24 hours \u00b1 3 hours postdose) and recorded at all study visits. At the first study visit, the patient had his/her BP measured in both arms; the arm in which the highest sitting DBP was found was used for all subsequent readings throughout the study. At each study visit, after the patient had been sitting for 5 minutes, DBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit.", "populationDescription": "The study was terminated and consequentially was underpowered for adequate statistical analysis", "reportingStatus": "POSTED", "timeFrame": "Baseline, 12 weeks", "groups": [{"id": "OG000", "title": "Valturna", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks."}, {"id": "OG001", "title": "Valturna + Amlodipine", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks."}, {"id": "OG002", "title": "Valturna + Chlorthalidone", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Percentage of Responders After Treatment", "description": "Responders are defined as patients with MSSBP \\<130 mmHg or a decrease from baseline in MSSBP of \u226520 mmHg", "populationDescription": "The study was terminated and consequentially was underpowered for adequate statistical analysis", "reportingStatus": "POSTED", "timeFrame": "Baseline, 12 weeks", "groups": [{"id": "OG000", "title": "Valturna", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks."}, {"id": "OG001", "title": "Valturna + Amlodipine", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks."}, {"id": "OG002", "title": "Valturna + Chlorthalidone", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving Blood Pressure Control After Treatment", "description": "Patient with blood pressure control is defined as patients achieving MSSBP \\<130 mmHg and MSDBP \\<80 mmHg.", "populationDescription": "The study was terminated and consequentially was underpowered for adequate statistical analysis", "reportingStatus": "POSTED", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Valturna", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks."}, {"id": "OG001", "title": "Valturna + Amlodipine", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks."}, {"id": "OG002", "title": "Valturna + Chlorthalidone", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Adverse Events, Serious Adverse Events and Death to Assess Safety and Tolerability of Treatment With Valturna and Chlorthalidone or Valturna and Amlodipine Versus Valturna Alone", "populationDescription": "Safety Set - Consists of all patients who received at least one dose of the double-blind study drug. Patients were analyzed according to the treatment that they received.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Valturna", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks."}, {"id": "OG001", "title": "Valturna + Amlodipine", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks."}, {"id": "OG002", "title": "Valturna + Chlorthalidone", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "138"}, {"groupId": "OG001", "value": "137"}, {"groupId": "OG002", "value": "142"}]}], "classes": [{"title": "Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "58"}]}]}, {"title": "Serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Valturna", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 138, "otherNumAffected": 23, "otherNumAtRisk": 138}, {"id": "EG001", "title": "Valturna + Amlodipine", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 137, "otherNumAffected": 16, "otherNumAtRisk": 137}, {"id": "EG002", "title": "Valturna + Chlorthalidone", "description": "At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 142, "otherNumAffected": 23, "otherNumAtRisk": 142}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 138}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 142}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 138}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 142}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 138}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 137}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 142}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000003920", "term": "Diabetes Mellitus"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000002752", "term": "Chlorthalidone"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "relevance": "LOW"}, {"id": "M5993", "name": "Chlorthalidone", "asFound": "Oropharyngeal", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}